Leadership & Career · Episode
Pavel Trofimov - Why Great Science Doesn't Sell Itself: Clinical Research's Commercial Blind Spot
Pavel Trofimov, founder of Lab-2-Business, joins Adam Walker to explore why great science doesn't sell itself, the limits of founder-led growth, embedded commercial teams and why AI-native clinical research companies are selling behaviour change.
Key insights
Great science needs a commercial engine
Pavel describes a clinical research industry where founders, scientists and operational leaders often handle delivery and business development themselves, rather than having dedicated commercial teams.
Embedded, not fractional
He works as an extended team member aligned on scope and outcomes, and avoids competing mandates.
AI adoption means behaviour change
For AI-native startups, winning business means persuading people to change how they work, measure and invoice-not simply introducing a new product.
Newsletter issue
Great science doesn't commercialise itself
Fifteen years in B2B sales, a hard look at the commercial blind spot in clinical research, and why AI-native startups are really selling behaviour change.
The written companion to this conversation with Pavel Trofimov. Browse the newsletter archive
Loading preview…
Get the newsletter
Every guest issue - the sharpest quotes, practical takeaways and a downloadable summary - straight to your inbox.